Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients with Triple Negative Breast Cancer

Last updated: February 11, 2025
Sponsor: Ohio State University Comprehensive Cancer Center
Overall Status: Active - Recruiting

Phase

N/A

Condition

Carcinoma

Metastatic Triple-negative Breast Cancer

Treatment

Survey Administration

Biospecimen Collection

Stress Management Therapy

Clinical Study ID

NCT05677802
OSU-22083
NCI-2022-08781
  • Ages > 18
  • Female

Study Summary

This clinical trial aims to see if patients with triple negative breast cancer can complete a biobehavioral stress reduction program that also addresses health related social needs (e.g., utilities, transportation, etc.). The stress reduction program is over ten weeks and includes stress reduction (e.g., progressive muscle relaxation), coping, problem solving, communication, and social support. Health related social needs will be evaluated at the beginning of the study, and referrals will be made to social work to help address those needs. The study will examine stress as reported by the patients and also use biological markers.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age >=18 years

  • Untreated newly diagnosed triple negative breast cancer

  • Stages I-III

Exclusion

Exclusion Criteria:

  • Prisoners

  • Male

  • Identifying as American Indian, Alaska Native, Asian, Native Hawaiian or OtherPacific Islander

  • Individuals not able to speak and understand English

  • Known personal history of ductal carcinoma in situ (DCIS) or invasive breast cancer

  • Stage IV breast cancer

Study Design

Total Participants: 40
Treatment Group(s): 4
Primary Treatment: Survey Administration
Phase:
Study Start date:
December 14, 2022
Estimated Completion Date:
January 31, 2026

Study Description

PRIMARY OBJECTIVES:

I Acceptability of the biobehavioral intervention will be determined using the Client Satisfaction Questionnaire (CSQ). CSQ is an 8-item self-report measure with item assessing different aspects of treatment satisfaction (e.g., quality of service, the degree to which needs were met, overall satisfaction).

III Tolerability of the biobehavioral intervention will be assessed by analyzing pre to post treatment change on the Profile of Mood States.

III Feasibility of the biobehavioral intervention will be assessed using three metrics:

  1. accrual number as a percentage of available patients approached; 2) number/percent of patients completing each BBI session; and, 3) number/percent of patients retained and completing 10 BBI sessions.

SECONDARY OBJECTIVE:

I. To examine the feasibility of collecting biomarkers--white blood cell count, C-reactive protein, Interleukin-6, TNF-alpha (α), systolic blood pressure, diastolic blood pressure, heart rate, total cholesterol, high-density lipoprotein; albumin, hemoglobin A1C, body mass index (BMI).

EXPLORATORY OBJECTIVE:

I. To test for pre/post effects of the biobehavioral stress reduction intervention on measures of stress (Impact of Events Scale), mood and psychological symptoms, and allostatic load.

OUTLINE:

Patients receive biobehavioral stress reduction intervention while on study. Patients undergo blood specimen collection at baseline and follow up, and have their medical records reviewed.

Connect with a study center

  • MetroHealth

    Cleveland, Ohio 44109
    United States

    Active - Recruiting

  • Ohio State University Comprehensive Cancer Center

    Columbus, Ohio 43210
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.